{"id":54472,"date":"2023-03-03T14:07:49","date_gmt":"2023-03-03T13:07:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/"},"modified":"2023-03-03T14:07:49","modified_gmt":"2023-03-03T13:07:49","slug":"affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/","title":{"rendered":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS"},"content":{"rendered":"<div>\n<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affinittx.com%2F&amp;esheet=53355503&amp;newsitemid=20230303005078&amp;lan=en-US&amp;anchor=Affini-T+Therapeutics%2C+Inc&amp;index=1&amp;md5=5a9b496b3a4271e96b1a9bf8d0a71bad\" rel=\"nofollow noopener\" shape=\"rect\">Affini-T Therapeutics, Inc<\/a>., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/5\/Affini-T_Therapeutics_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\"><\/a><\/p>\n<p>\n\u201c<!-- no quote -->We continue to see encouraging data from preclinical studies of AFNT-111 as we progress toward clinical investigation,\u201d said Lo\u00efc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. \u201c<!-- no quote -->We have observed high potency and specificity as well as a favorable tolerability profile, which provides encouraging support for our oncogenic driver programs. We look forward to presenting these data at the AACR Special Conference: Targeting Ras in Philadelphia.\u201d\n<\/p>\n<p>\nPresentation details are as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b><span class=\"bwuline\">Abstract #A009,<\/span><\/b><span class=\"bwuline\"> <b>Poster Session A<\/b>: March 6<sup>th<\/sup> 4:45-7:00 pm ET<\/span>: AFNT-111: a novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V &#8211; Presenting Authors: Gary Shapiro, Ph.D. and Michele Hoffmann, Ph.D., Affini-T Therapeutics\n<\/li>\n<\/ul>\n<p>\n<b>About Affini-T Therapeutics<\/b>\n<\/p>\n<p>\nAffini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faffini-t-therapeutics%2F%3Fesheet%3D52743098%26newsitemid%3D20220607006414%26lan%3Den-US%26anchor%3DLinkedIn%26index%3D4%26md5%3D1ebbb823b7d1d93a53b97259685da640&amp;esheet=53355503&amp;newsitemid=20230303005078&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=b5fa33c703e6b9d2d0e370cc23e2d44b\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Faffinit_tx%3Fesheet%3D52743098%26newsitemid%3D20220607006414%26lan%3Den-US%26anchor%3DTwitter%26index%3D5%26md5%3D5f7a006c8e96d439f77a04c392269ddb&amp;esheet=53355503&amp;newsitemid=20230303005078&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=d4e9ef30ac008048695f27b59580b3b1\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contacts<\/b><br \/>Danielle Cantey<br \/>\n<br \/>Evoke Canale<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;t&#x6f;&#58;&#x44;&#97;n&#x69;&#101;&#x6c;&#108;e&#x2e;&#67;&#x61;&#x6e;t&#x65;&#121;&#64;&#x65;&#118;&#x6f;&#107;e&#x67;&#114;&#x6f;&#117;p&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x44;a&#x6e;&#105;e&#x6c;&#108;&#x65;&#x2e;C&#x61;&#110;t&#x65;&#121;&#x40;&#101;v&#x6f;&#107;e&#x67;&#114;&#x6f;&#117;p&#x2e;&#99;&#x6f;&#x6d;<\/a><br \/>619-826-4657\n<\/p>\n<p>\n<b>Investor Contact<br \/>\n<br \/><\/b>Ailsa Dalgliesh, Ph.D.<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x61;i&#108;&#x73;a&#64;&#x61;&#102;&#x66;&#x69;&#110;&#x69;&#x74;&#116;&#x78;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">a&#105;&#x6c;&#x73;a&#64;&#97;&#x66;&#x66;i&#110;&#x69;&#x74;t&#120;&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras. \u201cWe continue to see encouraging data from preclinical studies of AFNT-111 as &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54472","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras. \u201cWe continue to see encouraging data from preclinical studies of AFNT-111 as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-03T13:07:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS\",\"datePublished\":\"2023-03-03T13:07:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/\"},\"wordCount\":297,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230303005078\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/\",\"name\":\"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230303005078\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"datePublished\":\"2023-03-03T13:07:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230303005078\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230303005078\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/","og_locale":"en_US","og_type":"article","og_title":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend","og_description":"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data for its lead oncogenic driver candidate targeting KRAS G12V, AFNT-111, will be presented at the AACR Special Conference: Targeting Ras. \u201cWe continue to see encouraging data from preclinical studies of AFNT-111 as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-03T13:07:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS","datePublished":"2023-03-03T13:07:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/"},"wordCount":297,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/","url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/","name":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","datePublished":"2023-03-03T13:07:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230303005078\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-data-from-lead-oncogenic-driver-candidate-at-aacr-special-conference-targeting-ras\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54472"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54472\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}